Cocrystal Pharma Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus

Reuters2025-10-10
<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus

Cocrystal Pharma Inc. has published a new investor presentation outlining its ongoing efforts in developing broad-spectrum antiviral drugs targeting influenza, norovirus, coronavirus, and respiratory viruses. The company highlights its proprietary structure-based drug discovery platform, which enables the design of antiviral candidates aimed at highly conserved viral regions. Key drug candidates in development include the oral pan-viral protease inhibitor CDI-988 for both norovirus and coronavirus infections, and the PB2 inhibitor CC-42344 for influenza A, currently in Phase 2a clinical trials. Cocrystal also notes the completion of GLP toxicology studies for certain assets and continues to explore government contract opportunities for pandemic preparedness. The company reports that its drug discovery platform may facilitate expedited regulatory pathways for its antiviral candidates. You can access the full presentation through the link below. https://www.cocrystalpharma.com

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment